Literature DB >> 8973589

Breast cancer prognostic significance of some modified urinary nucleosides.

A J Sasco1, F Rey, C Reynaud, J Y Bobin, M Clavel, A Niveleau.   

Abstract

The prognostic significance of six urinary modified nucleosides, 5-methylcytidine (5-MeCyd), 4-acetylcytidine (4-AcCyd), 1-methylinosine (1-MeIno), 1-methyladenosine (1-MeAdo), 7-methylguanosine (7-MeGua) and pseudouridine (psi-Urd) was evaluated in 68 breast cancer patients of the specialized cancer hospital of Lyon (France). Excretions of 1-MeIno and 1-MeAdo were significantly higher in patients hospitalized in the medical rather than surgical ward, reflecting more advanced disease, and also among patients who died within 5 years of follow-up as compared to those still alive. These results suggest an unfavourable prognostic significance of high urinary excretion of 1-MeIno and 1-MeAdo in breast cancer patients.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8973589     DOI： 10.1016/s0304-3835(96)04393-5

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  9 in total

1.  Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis.

Authors:  R Mazzucchelli; M Scarpelli; A Lopez-Beltran; L Cheng; H Bartels; P H Bartels; D S Alberts; R Montironi
Journal:  Int J Immunopathol Pharmacol       Date:  2011 Apr-Jun       Impact factor: 3.219

2.  Urinary volatile organic compounds as potential biomarkers for renal cell carcinoma.

Authors:  Dongchun Wang; Changsong Wang; Xin Pi; Lei Guo; Yue Wang; Mingjuan Li; Yue Feng; Ziwei Lin; Wei Hou; Enyou Li
Journal:  Biomed Rep       Date:  2016-05-20

Review 3.  The state-of-the-art determination of urinary nucleosides using chromatographic techniques "hyphenated" with advanced bioinformatic methods.

Authors:  Wiktoria Struck; Małgorzata Waszczuk-Jankowska; Roman Kaliszan; Michał J Markuszewski
Journal:  Anal Bioanal Chem       Date:  2011-02-27       Impact factor: 4.142

Review 4.  Metabolomics in cancer research and emerging applications in clinical oncology.

Authors:  Daniel R Schmidt; Rutulkumar Patel; David G Kirsch; Caroline A Lewis; Matthew G Vander Heiden; Jason W Locasale
Journal:  CA Cancer J Clin       Date:  2021-05-13       Impact factor: 286.130

5.  Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control.

Authors:  A Seidel; S Brunner; P Seidel; G I Fritz; O Herbarth
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

6.  Exometabolom analysis of breast cancer cell lines: Metabolic signature.

Authors:  Lucas Willmann; Thalia Erbes; Sebastian Halbach; Tilman Brummer; Markus Jäger; Marc Hirschfeld; Tanja Fehm; Hans Neubauer; Elmar Stickeler; Bernd Kammerer
Journal:  Sci Rep       Date:  2015-08-21       Impact factor: 4.379

7.  A review of applications of metabolomics in cancer.

Authors:  Richard D Beger
Journal:  Metabolites       Date:  2013-07-05

8.  Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer.

Authors:  Michael A Kiebish; Jennifer Cullen; Prachi Mishra; Amina Ali; Eric Milliman; Leonardo O Rodrigues; Emily Y Chen; Vladimir Tolstikov; Lixia Zhang; Kiki Panagopoulos; Punit Shah; Yongmei Chen; Gyorgy Petrovics; Inger L Rosner; Isabell A Sesterhenn; David G McLeod; Elder Granger; Rangaprasad Sarangarajan; Viatcheslav Akmaev; Alagarsamy Srinivasan; Shiv Srivastava; Niven R Narain; Albert Dobi
Journal:  J Transl Med       Date:  2020-01-07       Impact factor: 5.531

9.  Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer.

Authors:  S Dulong; Q Huang; P F Innominato; A Karaboue; M Bouchahda; A Pruvost; F Théodoro; L A Agrofoglio; R Adam; B Finkenstädt; F Lévi
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.